2. MAPK/ERK Pathway Metabolic Enzyme/Protease Cell Cycle/DNA Damage
  3. p38 MAPK HSP
  4. (±)-Iroxanadine

(±)-Iroxanadine  (Synonyms: BRX 005; BRX 235)

Cat. No.: HY-19399A
Handling Instructions

Molarity Calculator

(±)-Iroxanadine (BRX 005; BRX 235), a vasculoprotector, is a p38 kinase and HSP protein activator. (±)-Iroxanadine has the potential for atherosclerosis and vascular diseases research.

For research use only. We do not sell to patients.

(±)-Iroxanadine Chemical Structure

(±)-Iroxanadine Chemical Structure

CAS No. : 203805-20-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of (±)-Iroxanadine:

(±)-Iroxanadine Related Antibodies

Top Publications Citing Use of Products

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All HSP Isoform Specific Products:

View All Isoforms
HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

(±)-Iroxanadine (BRX 005; BRX 235), a vasculoprotector, is a p38 kinase and HSP protein activator. (±)-Iroxanadine has the potential for atherosclerosis and vascular diseases research[1].

In Vitro

(±)-Iroxanadine (BRX 235; 0.1 µM; 14-24 h) has cytoprotective properties in ECs[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(±)-Iroxanadine Related Antibodies

Cell Viability Assay[1]

Cell Line: Vascular endothelial cells (ECs)
Concentration: 0.1 µM
Incubation Time: 14 h, 24 h
Result: Showed cytoprotective properties.
Molecular Weight

260.33

Formula

C14H20N4O
CAS No.
SMILES

C1(C2=CC=CN=C2)=NOCC(CN3CCCCC3)N1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

(±)-Iroxanadine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(±)-Iroxanadine203805-20-3BRX 005 BRX 235BRX005BRX-005BRX235BRX 235BRX-235p38 MAPKHSPHeat shock proteinsvasculoprotectorp38 kinaseatherosclerosis and vascular diseasesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(±)-Iroxanadine
Cat. No.:
HY-19399A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.